TTRX · Turn Therapeutics Inc. · Financials
$12.69
-0.69 (-5.16%)
At close · Sep 11
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our capital resources may not be sufficient to fund operations through at least the next 12 months from the date that the accompanying unaudited condensed consolidated interim financial statements as of June 30, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$378.01M
Shares
29.79M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$3.19M
-80.6%
FY2025
Diluted EPS
-$0.12
-71.4%
FY2025
Operating Cash Flow
-$2.56M
-88.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 |
|---|---|---|---|
| $778.13K | $265.57K | $245.96K | |
| $6.2M | $5.59M | $1.55M | |
| — | $53K | $47K | |
| — | $52.75K | $47.48K | |
| $6.98M | $5.86M | $1.8M | |
| -$6.98M | -$5.86M | -$1.8M | |
| — | $29.58K | $28.71K | |
| -$1.46M | $2.66M | $28.71K | |
| -$8.45M | -$3.19M | -$1.77M | |
| USD/shares | -$0.29 | -$0.12 | -$0.07 |
| USD/shares | -$0.29 | -$0.12 | -$0.07 |
| shares | — | 27.72M | 26.64M |
| shares | — | 27.72M | 26.64M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.98×
EV/EBIT
—
Peer median 9.22×
P/E (TTM)
—
Peer median 11.89×
Peer medians compare against the 318 similar-size Biotechnology companies (of 536 listed).